Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.32 |
| ▸ | S100A4 | P26447 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | NSD2 | O96028 | 1/20 | 0.30 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.30 |
| ▸ | MIF | P14174 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28802735 | 0.73 | HPGD (0.41) | HPGDNPSR1ALDH1A1MEN1ALOX15 | |
| SCHEMBL14114151 | 0.73 | HPGD (0.41) | HPGDNPSR1ALDH1A1L3MBTL1MEN1 | |
| SCHEMBL31301094 | 0.73 | MEN1 (0.38) | HPGDNPSR1ALDH1A1MEN1ALOX15 | |
| SCHEMBL18918351 | 0.73 | HPGD (0.37) | HPGDNPSR1ALDH1A1MEN1ALOX15 | |
| SCHEMBL21383160 | 0.73 | MEN1 (0.38) | HPGDNPSR1ALDH1A1MEN1ALOX15 | |
| SCHEMBL11184460 | 0.68 | GPR84 (0.49) | HPGDNPSR1MEN1ALOX15KMT2A | |
| SCHEMBL2225691 | 0.68 | HPGD (0.34) | HPGDNPSR1MEN1ALOX15KMT2A | |
| SCHEMBL10721515 | 0.68 | NOTUM (0.45) | HPGDNPSR1ALDH1A1ALOX15TDP1 | |
| SCHEMBL11179601 | 0.68 | HPGD (0.34) | HPGDNPSR1ALDH1A1MEN1ALOX15 | |
| SCHEMBL5139730 | 0.65 | CDC25B (0.46) | HPGDNPSR1ALDH1A1L3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107266345-B | (hetero) arylcyclopropylamine compounds as LSD1 inhibitors | 奥瑞泽恩基因组学股份有限公司 | 2021-08-17 | — | — | CN | disclosed |
| EP-3736265-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | Oryzon Genomics, S.A. (ES) | 2020-11-11 | — | — | EP | disclosed |
| EP-2768805-B1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2020-03-25 | — | — | EP | disclosed |
| US-10329256-B2 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | ORYZON GENOMICS, S.A. (ES) | 2019-06-25 | — | — | US | disclosed |
| US-20180354902-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS S.A. (ES) | 2018-12-13 | — | — | US | disclosed |
| US-9944601-B2 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | ORYZON GENOMICS, S.A. (ES) | 2018-04-17 | — | — | US | disclosed |
| US-20170008844-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS S.A. (ES) | 2017-01-12 | — | — | US | disclosed |
| US-9487512-B2 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | ORYZON GENOMICS S.A. (ES) | 2016-11-08 | — | — | US | disclosed |
| US-20150025054-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS S.A. (ES) | 2015-01-22 | — | — | US | disclosed |
| EP-2768805-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | Oryzon Genomics, S.A. (ES) | 2014-08-27 | — | — | EP | disclosed |
| EP-1007523-B9 | INDOLE AND 2,3-DIHYDROINDOLE DERIVATIVES, THEIR PREPARATION AND USE | LUNDBECK & CO AS H (DK) | 2004-09-08 | — | — | EP | disclosed |
| US-6727263-B2 | SEROTONINE REUPTAKE INHIBITOR; ANTIDEPRESSANTS; SIDE EFFECT REDUCTION | H. LUNDBECK A/S (DK) | 2004-04-27 | — | — | US | disclosed |
| EP-1007523-B1 | INDOLE AND 2,3-DIHYDROINDOLE DERIVATIVES, THEIR PREPARATION AND USE | LUNDBECK & CO AS H (DK) | 2003-10-22 | — | — | EP | disclosed |
| US-20030050306-A1 | Novel heteroaryl derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2003-03-13 | — | — | US | disclosed |
| US-20030018050-A1 | Indole and 2,3-dihydroindole derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2003-01-23 | — | — | US | disclosed |
| US-6476035-B1 | Indole and 2,3-dihydroindole derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2002-11-05 | — | — | US | disclosed |
| EP-1246820-A1 | NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE | H. LUNDBECK A/S (DK) | 2002-10-09 | — | — | EP | disclosed |
| WO-2001049683-A1 | NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE | H. LUNDBECK A/S (DK) | 2001-07-12 | — | — | WO | disclosed |
| EP-1007523-A1 | INDOLE AND 2,3-DIHYDROINDOLE DERIVATIVES, THEIR PREPARATION AND USE | H. LUNDBECK A/S (DK) | 2000-06-14 | — | — | EP | disclosed |
| WO-1999005140-A1 | INDOLE AND 2,3-DIHYDROINDOLE DERIVATIVES, THEIR PREPARATION AND USE | H. LUNDBECK A/S (DK) | 1999-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050306-A1 | Novel heteroaryl derivatives, their preparation and use | CRBN, CDR2, DRD3 | HPGD 4499/4885NPSR1 44/4885ALDH1A1 2108/4885 |
| US-20180354902-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | HPGD 1663/4885NPSR1 3133/4885ALDH1A1 562/4885 |
| US-20170008844-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | HPGD 1663/4885NPSR1 3133/4885ALDH1A1 562/4885 |
| US-20030018050-A1 | Indole and 2,3-dihydroindole derivatives, their preparation and use | TPH1, HTR1A, HTR3A | HPGD 976/4885NPSR1 53/4885ALDH1A1 635/4885 |
| US-20150025054-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | HPGD 1663/4885NPSR1 3133/4885ALDH1A1 562/4885 |
| US-10329256-B2 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | KDM1B, KDM1A, KDM2A | HPGD 1663/4885NPSR1 3133/4885ALDH1A1 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.